Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom

Back to Search
Print
Bookmark Trial

NCT01012245

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- patients with ocular hypertension or glaucoma, defined by SmPC

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- defined by SmPC

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Glaucoma, Ocular HypertensionNon-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom NCT01012245
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionA Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost. NCT00638742
  1. Artesia, California
  2. Atlanta, Georgia
  3. Atlanta, Georgia
  4. North Dartmouth, Massachusetts
  5. Minneapolis, Minnesota
  6. Durham, North Carolina
  7. Koebenhavn OE,
  8. Catania,
  9. Coimbra,
  10. Lisboa,
  11. Mayfair West,
  12. Madrid,
  13. Madrid,
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionComparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US NCT00847483
  1. Belleflower, California
  2. Inglewood, California
  3. San Diego, California
  4. San Diego, California
  5. San Francisco, California
  6. Gainesville, Florida
  7. Lakeland, Florida
  8. Ormond Beach, Florida
  9. Atlanta, Georgia
  10. Bloomingdale, Illinois
  11. Evansville, Indiana
  12. Louisville, Kentucky
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bangor, Maine
  16. Kansas City, Missouri
  17. Kansas City, Missouri
  18. Omaha, Nebraska
  19. Las Vegas, Nevada
  20. Bloomfield, New Jersey
  21. Willingboro, New Jersey
  22. Charlotte, North Carolina
  23. Winston-Salem, North Carolina
  24. Streetsboro, Ohio
  25. Oklahoma City, Oklahoma
  26. Tulsa, Oklahoma
  27. Pittsburgh, Pennsylvania
  28. Charleston, South Carolina
  29. Charleston, South Carolina
  30. Charleston, South Carolina
  31. Maryville, Tennessee
  32. Memphis, Tennessee
  33. Dallas, Texas
  34. El Paso, Texas
  35. Houston, Texas
  36. Layton, Utah
  37. Norfolk, Virginia
  38. Norfolk, Virginia
  39. Virginia Beach, Virginia
  40. Wenatchee, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionEfficacy and Tolerability of Xalatan in Patients NCT00950690
  1. Alexandria,
  2. Jeddah,
  3. Umm Al Quwain,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Official Title Project "XCHANGE" Non-Interventional Study
Brief Summary Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions. Data were entered into an electronic case report form.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population patients with glaucoma or ocular hypertension treated by office-based ophthalmologists
Condition
  • Glaucoma
  • Ocular Hypertension
Intervention Other: no intervention
Study Groups/Cohorts patients with glaucoma and ocular hypertension
Intervention: Other: no intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: December 11, 2009)		28812
Original Actual Enrollment
 (submitted: November 11, 2009)		28871
Actual Study Completion Date December 2008
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • patients with ocular hypertension or glaucoma, defined by SmPC

Exclusion Criteria:

  • defined by SmPC
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01012245
Other Study ID Numbers 912-OPT-0091-131
A6111100, 912-OPT-0091-131
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2010